RANKL inhibition also significantly suppressed the proliferation of tumor organoids derived from BRCA1 mutant human breast biopsy specimens, and RANKL/RANK pathway blockade strongly reduced tumorigenesis in patient-derived xenograft (PDX) breast tumor mouse model (91). Here, TNFRSF11A is linked to neoplasm.